Navigation Links
Renhuang Announces Appointment of Interim CFO

Renhuang Announces Appointment of Interim CFO -- HARBIN, China, Aug. 20 /PRNewswire-Asia-FirstCall/ --

Advanced Search Search

  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Health Care & Hospitals, Medical Pharmaceuticals, Pharmaceuticals, Personnel Announcements Click to view news release full screen  

Renhuang Announces Appointment of Interim CFO


HARBIN, China, Aug. 20 /PRNewswire-Asia-FirstCall/ -- Renhuang Pharmaceuticals, Inc. (NYSE Amex: CBP) ("Renhuang" or the "Company"), a developer, manufacturer and distributor of botanical products, bio-pharmaceuticals and traditional Chinese medicines ("TCM"), today announced that, it has appointed Ms. Xiaoying Lu as its Interim Chief Financial Officer ("CFO"), while the Company seeks a permanent replacement.

Reporting directly to Mr. Shaoming Li, the Company's Chairman and Chief Executive Officer, Ms. Lu will be responsible for managing all financial functions, including, financial management, reporting, risk management and managing the financial budget, while Renhuang continues to search for a new CFO. Upon his or her appointment, Ms. Lu will transition to the role of an Assistant to the CFO to ensure a seamless transition.

Prior to joining Renhuang's financial department on August 13, Ms. Lu was director of accounting at Harbin Santong Energy Limited Company, an enterprise with more than 500 employees, where she served for over six years. Ms. Lu graduated from Harbin Institute of Economic Management with a Bachelor's degree in Accounting. She is a certified Senior Accountant, which requires passing the national senior accountant exam and meeting rigorous standards for work experience and foreign language skills. Ms. Lu is also in process of completing the requisites to earn her China CPA (Certified Public Accountant).

"We are excited to have Ms. Lu as part of Renhuang's management team and extend a warm welcome to her. Her professional experience will make her a valuable asset to our finance team," said Mr. Shaoming Li, the Company's Chairman and Chief Executive Officer. "We have tremendous confidence in her ability to manage Renhuang's finance operations during this interim period, particularly because she shares Renhuang's dedication and commitment to instituting and maintaining high standards of accuracy and transparency."

About Renhuang Pharmaceuticals, Inc.

Renhuang Pharmaceuticals, Inc. is engaged in the research, development, manufacturing, and distribution of botanical products, bio-pharmaceutical products, and traditional Chinese medicines ("TCM"), in the People's Republic of China. All of the Company's products are produced at its three GMP-certified production facilities in Ah City, Dongfanghong and Qingyang. The Company distributes its botanical anti-depression and nerve-regulation products, biopharmaceutical products, and botanical antibiotic and OTC TCMs. through its network of over 3,000 distributors and over 70 sales centers across 24 provinces in China. Company Website: .

Safe Harbor Statement

This press release contains certain statements that may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are based upon management's beliefs, assumptions and expectations of the Company's future operations and economic performance, taking into account the information currently available to management. These statements are not statements of historical fact. Forward-looking statements involve risks and uncertainties, some of which are not currently known that may cause actual results, performance or financial condition to be materially different from the expectations of future results, performance or financial condition expressed or implied in any forward-looking statements. These forward-looking statements are based on current plans and expectations and are subject to a number of uncertainties including, but not limited to, the Company's ability to manage expansion of its operations effectively, ability to find a new CFO, and other factors detailed in the Company's annual report on Form 10-K and other filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented herein.

For more information, please contact: Company Contact: Renhuang Pharmaceuticals, Inc. Ms. Portia Tan, IR Contact Phone: +86-451-8260-2162 Email: CCG Investor Relations: Mr. Mark Collinson, Partner Phone: +1-310-954-1343 (Los Angeles) Email: Web: Mr. Crocker Coulson, President Phone: +1-646-213-1915 (New York) Email:

SOURCE Renhuang Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Renhuang Receives Patent for Product Package Design for Compound Honeysuckle Granules
2. Renhuang Showcases its All Natural Products at 45th China National New and Special Drugs Fair
3. Renhuang Signs Exclusive Purchase Agreement for Siberian Ginseng
4. Renhuang Begins Trading on NYSE Amex
5. Renhuang Pharmaceuticals Receives Approval to List on the NYSE Amex
6. Renhuang Pharmaceuticals Exhibits Siberian Ginseng Products at the 21st China Harbin International Economic and Trade Fair
7. Renhuang to Launch New Bio-pharmaceutical Product - Ginseng and Deer Antler Extract
8. Renhuang to Launch New All-Natural Anti-depressant and Nerve Regulation Product - Compound Schisandra Tablets
9. Renhuang Wins Bid to Supply All-Natural Products to Guangzhou Military District
10. Renhuang Schedules Conference Call to Discuss FY 2010 Second Quarter Results
11. Renhuang Appoints PricewaterhouseCoopers to Develop a SOX 404 Compliance Program
Post Your Comments:
(Date:11/30/2015)... November 30, 2015 Elbit Imaging ... "Company") announced today that it was informed by InSightec Ltd. ... Safety (MFDS) has approved its Exablate Neuro system to ... --> --> Insightec,s Exablate Neuro platform ... that combines two technologies: Focused Ultrasound, which is used ...
(Date:11/29/2015)... Nov. 29, 2015  The GE Health Cloud 1 ... Society of North America (RSNA) meeting ... healthcare industry, the new cloud ecosystem and its applications will ... care pathways and multidisciplinary teams – both inside and outside ... and CEO of GE. "As the digital industrial leader, we ...
(Date:11/27/2015)... Niederlande, November 27, 2015 ... bei fortgeschrittenem Krebs.   --> Ein ... fortgeschrittenem Krebs.   --> Ein ... fortgeschrittenem Krebs.   Clinical Cancer Research ... Clinical Cancer Research vom 6. November ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... November 30, 2015 , ... ... announce the speakers for “Value-Based Payer-Provider Partnerships: Three Case Studies,” an upcoming ... value-based care arrangements: Essentia Health and UCare, MissionPoint Health Partners, and Intel ...
(Date:11/30/2015)... ... November 30, 2015 , ... Insightra ... TIGR® Matrix Surgical Mesh technology for soft tissue repair in the US via ... a long-term resorbable surgical mesh intended to support and reinforce soft tissue for ...
(Date:11/30/2015)... ... , ... GKhair & Tibolli team members and artists were excited and proud ... 8th and 9th at the Puerto Rico Convention Center, San Juan Puerto Rico. The ... of the line fashion journalists. The San Juan Beauty Show carries immense credibility among ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... to announce their strategic partnership at the Radiological Society of North America ... and Winscribe, global providers of cutting-edge dictation and speech-enabled documentation software, announced ...
(Date:11/30/2015)... Miami, FL (PRWEB) , ... November 30, 2015 ... ... manufacturer and engineer of patented products, announces the Unstoppable Swappables, a household invention ... Window Coverings Industry makes $2 billion a year and is growing at 2.6%," ...
Breaking Medicine News(10 mins):